2.73
2.73 (0%)
As of Feb 14, 2025
Gain Therapeutics, Inc. [GANX]
Source:
Company Overview
Gain Therapeutics, Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
| Country | United States |
| Headquarters | bethesda, maryland |
| Phone Number | (301) 500-1556 |
| Industry | |
| CEO | Matthias Alder |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-20.4 |
| Net Income | $-20.4 |
| Net Cash | $-1.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -132.8% |
| Profit as % of Stockholder Equity | -278.1% |
Management Effectiveness
| Return on Equity | -278.1% |
| Return on Assets | -168.4% |
| Turnover Ratio | |
| EBITA | $-20.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $12.1 |
| Total Liabilities | $4.8 |
| Operating Cash Flow | $-18.9 |
| Investing Cash Flow | $5 |
| Financing Cash Flow | $13 |
